1. [Etolip and Lipanthyl in the treatment of hyperlipoproteinemia]
- Author
-
R, Ceska, J, Sobra, R, Procházková, and M, Kvasilová
- Subjects
Male ,Hyperlipoproteinemias ,Fenofibrate ,Humans ,Female ,Clofibrate ,Middle Aged ,Propionates ,Hypolipidemic Agents - Abstract
Within the framework of clinical tests of Etolip (ethophylline clofibrate cps. 125 mg, Pharmaceutical Research Institute Modra) this preparation was administered to 28 patients with different types of hyperlipoproteinaemia in a specialized clinic for disorders of the lipid metabolism. The period of administration was four weeks, the dose 2 cps. twice a day. The effect of this new hypolipidaemic drug was compared with that of Lipathyl. Treatment with Etolip did not affect significantly the cholesterol and triacylglycerol levels, and the concentrations of apolipoprotein B and LDL-cholesterol did not change significantly. All these parameters were affected favourably and significantly by Lipanthyl. Etolip treatment had the favourable effect of elevating the HDL-cholesterol and apolipoprotein A-I level. Etolip was well tolerated by patients and no undesirable side-effects developed. The effects of Etolip as a hypolipidaemic agent are relatively small and are markedly lower than the effect of other registered hypolipidaemics available in the CSSR.
- Published
- 1990